Extended Data Fig. 2. Compliance on randomized treatment over time by baseline SGLT2i use (participants planned to be on treatment).

The lines represent the proportion of participants compliant on treatment until the planned end-of-treatment visit. Compliance on-treatment period: all days from the date of first dose to the end of the in-trial period where a dose has been administered. The period could include non-consecutive time intervals, and the dose did not have to be the target dose. SGLT2i, sodium-glucose co-transporter-2 inhibitors.